Approval of Mynzepli: The European Commission has approved Mynzepli (aflibercept) as a biosimilar to Eylea for treating various retinal diseases, including neovascular age-related macular degeneration (AMD).
Clinical Study Results: The approval is supported by extensive clinical data, including a confirmatory study that demonstrated therapeutic equivalence between Mynzepli and Eylea in patients with neovascular AMD.
Accessibility and Impact: Alvotech and Advanz Pharma emphasize the importance of this approval in improving access to effective therapies for millions of Europeans affected by retinal diseases.
Product Availability: Mynzepli will be available in both pre-filled syringes and vials, providing treatment options for conditions such as diabetic macular edema and visual impairment due to retinal vein occlusion.
ALVO
$5.4+Infinity%1D
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.570
Low
8.00
Averages
10.67
High
14.00
Current: 5.570
Low
8.00
Averages
10.67
High
14.00
Barclays
Glen Santangelo
Underweight
initiated
$5
2025-12-08
Reason
Barclays
Glen Santangelo
Price Target
$5
2025-12-08
initiated
Underweight
Reason
Barclays analyst Glen Santangelo initiated coverage of Alvotech with an Underweight rating and $5 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
Morgan Stanley
Overweight
downgrade
$14 -> $10
2025-12-03
Reason
Morgan Stanley
Price Target
$14 -> $10
2025-12-03
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Alvotech to $10 from $14 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
UBS
Buy
to
Buy
downgrade
$13 -> $10
2025-11-18
Reason
UBS
Price Target
$13 -> $10
2025-11-18
downgrade
Buy
to
Buy
Reason
UBS lowered the firm's price target on Alvotech to $10 from $13 and keeps a Buy rating on the shares.
Northland
Outperform
to
NULL
downgrade
$28 -> $10
2025-11-04
Reason
Northland
Price Target
$28 -> $10
2025-11-04
downgrade
Outperform
to
NULL
Reason
Northland lowered the firm's price target on Alvotech to $10 from $28 and keeps an Outperform rating on the shares after the company received a Complete Response Letter for AVT05 following FDA inspection findings at its Reykjavik site. The company lowered FY25 revenue and adjusted EBITDA guidance as a result, notes the firm, which expects outstanding BLAs for AVT03 and AVT06 to be delayed as well.
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
